Is the Galleri multi-cancer blood test worth it? A doctor explains real-world performance data and explains why no major ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced topline results from the landmark, randomized, controlled NHS-Galleri ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

Feb 20 (Reuters) - Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker ...

GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.

Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...

Add Yahoo as a preferred source to see more of our stories on Google. Pancreatic cancer is the third leading cause of cancer-related deaths, trailing behind lung cancer and colorectal cancer, a trend ...